JPH0251543B2 - - Google Patents
Info
- Publication number
- JPH0251543B2 JPH0251543B2 JP20510985A JP20510985A JPH0251543B2 JP H0251543 B2 JPH0251543 B2 JP H0251543B2 JP 20510985 A JP20510985 A JP 20510985A JP 20510985 A JP20510985 A JP 20510985A JP H0251543 B2 JPH0251543 B2 JP H0251543B2
- Authority
- JP
- Japan
- Prior art keywords
- carnitine
- milk
- permeate
- column
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 35
- 235000013336 milk Nutrition 0.000 claims description 15
- 239000008267 milk Substances 0.000 claims description 15
- 210000004080 milk Anatomy 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 14
- 238000011033 desalting Methods 0.000 claims description 11
- 238000004440 column chromatography Methods 0.000 claims description 6
- 235000013365 dairy product Nutrition 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 239000006227 byproduct Substances 0.000 claims description 5
- 238000000909 electrodialysis Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003729 cation exchange resin Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000012466 permeate Substances 0.000 description 16
- 229960004203 carnitine Drugs 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 235000008476 powdered milk Nutrition 0.000 description 4
- 235000013350 formula milk Nutrition 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000020187 evaporated milk Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000020610 powder formula Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
【発明の詳細な説明】
産業上の利用分野
本発明は、乳中に微量成分として含まれるＬ−
カルニチンを、乳又は乳製品の限外濾過処理工程
で副産する濾液より分離、採取して調製する方法
に関する。DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention relates to L-
The present invention relates to a method for preparing carnitine by separating and collecting it from a filtrate that is a by-product in the ultrafiltration process of milk or dairy products.
Ｌ−カルニチンは、ミトコンドリアにおける脂
肪酸酸化に関与するビタミン様物質であつて、補
酵素Ａの円滑な作用を維持するためには必須の物
質である。したがつて、Ｌ−カルニチンを添加す
ることにより脂肪酸酸化が亢進された積された脂
肪は減少するので、Ｌ−カルニチンは肥満防止に
も効果があるとの報告もみられる。 L-carnitine is a vitamin-like substance involved in fatty acid oxidation in mitochondria, and is an essential substance for maintaining the smooth action of coenzyme A. Therefore, there are reports that L-carnitine is also effective in preventing obesity, since the addition of L-carnitine reduces accumulated fat due to accelerated fatty acid oxidation.
また、Ｌ−カルニチンは、ミトコンドリア系が
正常に機能しないことに起因する種々の障害にも
有効とされている。 Furthermore, L-carnitine is said to be effective against various disorders caused by abnormal functioning of the mitochondrial system.
従来の技術的背景
本来、新生児期では肝でのカルニチン合成能が
未熟であるため、大部分を母乳乃至は調製粉乳か
ら接種しいなければならい。而して、調製粉乳は
カルニチンを含有する牛乳を素材としているため
特に問題はないが、代謝異常症児の治療に用いら
れる治療ミルクは、アミノ酸混合粉末を主原料と
して調製したものであつて、カルニチンを
10nmlo／ml以下の少量しか含んでおらず、した
がつて、このような特殊ミルクを与えて栄養を行
なつた場合には、脂肪酸化およびケトン体産生が
円滑に行なわれ難く、その結果新生児期の脳発達
上問題があるとされている。Conventional Technical Background In the neonatal period, the ability to synthesize carnitine in the liver is immature, so most of the inoculation must come from breast milk or formula milk. Formulated milk is not particularly problematic because it is made from milk containing carnitine, but the therapeutic milk used to treat children with metabolic disorders is prepared using amino acid mixed powder as the main ingredient. carnitine
It contains only a small amount, less than 10nmlo/ml, and therefore, when such special milk is given for nutrition, fatty acid oxidation and ketone body production are difficult to be carried out smoothly, and as a result, the neonatal period is It is said that there are problems with brain development.
また、カルニチンは化学的に合成可能である
が、しかし、合成により得られるものはＤ−、Ｌ
−異性体の混合物（ラセミ体）であり、天然に存
在しないＤ−カルニチンは生体で利用されず、有
害であるとの指滴もある。そのため、ラセミ体の
分割によるＬ−カルニチンの分離もみられている
が、複雑な操作を必要とするので、上記分離は実
際上非常に困難である。因に、合成品は医薬外の
食品添加物としては認められていない。したがつ
て、我国では現在食品に添加し得るＬ−カルニチ
ン強化剤は存在せず、治療用として試験的に輸入
されているのみである。 Additionally, carnitine can be chemically synthesized, but those obtained by synthesis are D-, L-
- D-carnitine, which is a mixture of isomers (racemate) and does not exist naturally, is not utilized by living organisms and some say it is harmful. Therefore, separation of L-carnitine by resolution of the racemate has been observed, but the above separation is actually very difficult because it requires complicated operations. Incidentally, synthetic products are not approved as non-medicinal food additives. Therefore, there are currently no L-carnitine fortifiers that can be added to foods in Japan, and they have only been imported on a trial basis for therapeutic use.
発明が解決しようとする問題点
本発明者は、上述したような状況に鑑み、代謝
異常児用の粉乳等へ添加してＬ−カルニチンを強
化するのに適したＬ−カルニチン含有天然素材の
調製について検討した結果、乳又は乳製品を限外
濾過処理する工程で副産する濾液（パーミエイト
と称せられるので、以下パーミエイトという）か
らＬ−カルニチンを豊富に含む画分を分離、採取
することに成功し本発明をなすに至つた。Problems to be Solved by the Invention In view of the above-mentioned circumstances, the present inventor has developed an L-carnitine-containing natural material suitable for adding to powdered milk for children with metabolic disorders to fortify L-carnitine. As a result of research, we succeeded in separating and collecting a fraction rich in L-carnitine from the filtrate (called permeate, hereinafter referred to as permeate) that is a by-product during the ultrafiltration process of milk or dairy products. This led to the present invention.
すなわち、本発明は、上記パーミエイトもしく
は該パーミエイトを脱塩、乾燥して得られるパー
ミエイト粉末の溶液からＬ−カルニチンを分離し
て調製する方法を提供することを目的とする。 That is, an object of the present invention is to provide a method for separating and preparing L-carnitine from the above permeate or a solution of permeate powder obtained by desalting and drying the permeate.
以下本発明を詳しく説明する。 The present invention will be explained in detail below.
発明の構成
本発明の構成上の特徴は、乳又は乳製品を限外
濾過処理する際に副産されるパーミエイトを脱塩
処理して得られる液、もしくは該液を更に乾燥し
て得られる粉末の溶液を、カラムクロマトグラフ
イーに付して上記液もしくは上記溶液中のＬ−カ
ルニチンを吸着させた後、溶出してＬ−カルニチ
ン画分を採取することにある。Structure of the Invention The structure of the present invention is characterized by a liquid obtained by desalting permeate, which is a by-product during ultrafiltration of milk or dairy products, or a powder obtained by further drying the liquid. The solution is subjected to column chromatography to adsorb the above solution or L-carnitine in the above solution, and then eluted to collect the L-carnitine fraction.
ここで出発原料として用いる“乳”とは、生
乳、牛乳、特別牛乳、部分脱脂乳、脱脂乳等を意
味し、また、“乳製品”とは濃縮ホエー、濃縮乳、
脱脂濃縮乳、無糖練乳、無糖脱脂練乳、全粉乳、
脱脂粉乳、ホエイパウダー、調製粉乳を意味す
る。 "Milk" used as a starting material here means raw milk, cow's milk, special milk, partially skimmed milk, skim milk, etc., and "dairy products" include concentrated whey, concentrated milk,
Skimmed concentrated milk, evaporated milk, unsweetened skimmed condensed milk, whole milk powder,
Means skimmed milk powder, whey powder, and infant formula.
問題点を解決するための手段
本発明では、上記パーミエイトに脱塩処理、好
ましくは電気透析による脱塩処理を施してそれに
含有されるミネラル類、有機酸類を除去したもの
をカラムクロマトグラフイに付する。Means for Solving the Problems In the present invention, the permeate is desalinated, preferably by electrodialysis to remove minerals and organic acids contained therein, and then subjected to column chromatography. do.
ここで、脱塩処理を施す理由は、カラムクロマ
トグラフイーにおけるカルニチンの吸着効率を上
げるため、及び分取後のミネラル成分の規格化が
容易であることである。また、その際電気透析法
が好ましい理由は、カラムに通したときのPH変動
が少ないこと、及びランニングコストが安いこと
に因る。 Here, the reason for performing the desalting treatment is to increase the adsorption efficiency of carnitine in column chromatography and to facilitate standardization of mineral components after fractionation. Moreover, the reason why electrodialysis is preferable in this case is that there is little PH fluctuation when passing through the column, and the running cost is low.
上記脱塩処理に際しては、パーミエイトを濃縮
して過飽和状態に至らし、次いで５℃以下に冷却
することにより該パーミエイト中の乳糖を沈澱さ
せて除去しておくことが脱塩効果上好ましい。ま
た、このようにして乳糖を除去したパーミエイト
の上燈を上述のように脱塩処理する場合、30℃程
度に加温して電気透析を行なうと脱塩を一そう効
果的に行なうことができる。 In the above-mentioned desalting treatment, it is preferable from the viewpoint of the desalting effect that the permeate is concentrated to reach a supersaturated state and then cooled to 5° C. or lower to precipitate and remove the lactose in the permeate. In addition, when desalting the permeate tops from which lactose has been removed in this way as described above, desalting can be done more effectively by heating them to about 30°C and performing electrodialysis. .
本発明ではカラムクロマトグラフイーとして通
常強酸性陽イオン交換樹脂を充填したカラムを用
い、該カラムに上記により脱塩処理したパーミエ
イトを通してＬ−カルニチン画分をカラムに吸着
させ、次いでカラムを精製水で十分に洗浄して残
存する乳糖及び蛋白等を流出さた後、吸着したＬ
−カルニチンをアルカリ溶液、例えばアンモニア
水を用いて溶出させる。ここで強酸性陽イオン交
換樹脂を用いるのは、脱塩後のパーミエイトが酸
性であつて、カルニチンは陽荷電と推定されるこ
とによる。 In the present invention, a column packed with a strongly acidic cation exchange resin is usually used for column chromatography, and the L-carnitine fraction is adsorbed onto the column by passing the desalted permeate through the column, and then the column is filled with purified water. After thorough washing to remove remaining lactose and protein, the adsorbed L
- Carnitine is eluted using an alkaline solution, for example aqueous ammonia. The reason why a strongly acidic cation exchange resin is used here is that permeate after desalting is acidic and carnitine is presumed to be positively charged.
なお、本発明では、上述のようにして脱塩処理
したパーミエイトを噴霧乾燥等により乾燥して粉
末化して得られるパーミエイト粉末を水に溶解し
た溶液を上述のようにしてカラムクロマトグラフ
イーに付してＬ−カルニチンを吸着させ、洗浄後
溶出してＬ−カルニチンを得ることもできる。 In the present invention, permeate desalinated as described above is dried and powdered by spray drying or the like, and a solution obtained by dissolving permeate powder in water is subjected to column chromatography as described above. L-carnitine can also be obtained by adsorbing L-carnitine and eluting it after washing.
次に、上記によりカラムから溶出したＬ−カル
ニチン画分は濃縮した後、乾燥して粉末化しても
よいが、Ｌ−カルニチン粉末は吸湿性が著しく強
くので、濃縮したものを乳糖等に倍散させ、倍散
末として使用するのが実用上好ましい。 Next, the L-carnitine fraction eluted from the column as described above may be concentrated and then dried to form a powder. However, since L-carnitine powder is extremely hygroscopic, the concentrated fraction may be triturated with lactose, etc. Practically speaking, it is preferable to use the powder as a powder.
このようにして得られる乳糖倍散末Ｌ−カルニ
チンは、代謝異常症児用粉乳、育児用調製粉乳、
および健康食品やスポーツ用食へのＬ−カルニチ
ン強化剤として有効に適用できる。 The lactose-dissolved powder L-carnitine thus obtained can be used for powdered milk for children with metabolic disorders, infant formula powder,
It can also be effectively applied as an L-carnitine fortifier to health foods and sports foods.
叙上のとおり、本発明によると、従来、乳又は
乳製品を限外濾過処理する工程で副産し、ほとん
ど利用さることなく廃棄処理されたていたパーミ
エイトを出発原料として用いて、脂肪酸酸化程上
重要な生化学的役割を果すＬ−カルニチンを有利
に製造し得るので、特にＬ−カルニチンの要求度
の高い新生児用粉乳ならびに代謝異常症児用粉乳
の調製上非常に有益であると言える。 As mentioned above, according to the present invention, permeate, which was conventionally produced as a by-product in the process of ultrafiltration of milk or dairy products and was discarded without being used, is used as a starting material to carry out the fatty acid oxidation process. Since L-carnitine, which plays an important biochemical role, can be advantageously produced, it can be said to be very useful, especially in the preparation of powdered milk for newborns and powdered milk for children with metabolic disorders, which have a high demand for L-carnitine.
以下に実施例を示して本発明を更に具体的に説
明する。 EXAMPLES The present invention will be explained in more detail with reference to Examples below.
実施例
牛乳56Kgを常法に従つて限外濾過処理してーミ
エイト45Kg（全固型分５％）を得た。Example 56 kg of milk was subjected to ultrafiltration according to a conventional method to obtain 45 kg of milk (total solid content: 5%).
得られたパーミエイトを濃縮して全固分20〜25
％にしたものを５℃以下に冷却して乳糖を析出さ
せ、デカンテーシヨンを行なつて上燈９を回吸
した。 Concentrate the obtained permeate to a total solids of 20 to 25
% was cooled to below 5° C. to precipitate lactose, decantation was performed, and the upper light 9 was sucked back.
得られた上澄を25〜30℃に加して電気透析に付
して脱塩を行なつた。脱塩率は99.36％に達した。 The obtained supernatant was heated to 25 to 30°C and subjected to electrodialysis for desalting. The desalination rate reached 99.36%.
次に、脱塩処理して得られた液を、強酸性陽イ
オン交換樹脂ダイアイオンSK−1B（三菱化成社）
１を充填したガラスカラムに通した後、精製水
４を用いてカラムを洗浄し、ついで1.5Nアン
モニア水を用いてカラムに吸着したＬ−カルニチ
ン画分を溶出した。得られた溶出液を300mlに濃
縮し、これに乳糖100ｇを添加、混合した後、凍
結乾燥を行なつて乳糖倍散末Ｌ−カルニチン（カ
ルニチン2000mg／乳糖100ｇ）を得た。なお、カ
ルニチンは遊離型：1680mg、アシル（Acyl）
型：320mgから成つていた。 Next, the solution obtained by desalination treatment was used as a strong acidic cation exchange resin Diaion SK-1B (Mitsubishi Kasei Corporation).
After passing through a glass column packed with 1, the column was washed with purified water 4, and then the L-carnitine fraction adsorbed on the column was eluted with 1.5N ammonia water. The obtained eluate was concentrated to 300 ml, 100 g of lactose was added thereto, mixed, and freeze-dried to obtain lactose-dispersed powder L-carnitine (2000 mg of carnitine/100 g of lactose). In addition, carnitine is free form: 1680mg, Acyl
Type: Consisted of 320mg.
Claims (1)
される濾液を脱塩処理して得られる液、もしくは
該液を更に乾燥して得られる粉末の溶液を、カラ
ムクロマトグラフイーに付して上記液もしくは上
記溶液中のＬ−カルニチンを吸着させた後、溶出
することを特徴とするＬ−カルニチンの調製方
法。 ２ 脱塩処理を電気透析により行なう特許請求の
範囲第１項記載の調製方法。 ３ カラムクロマトグラフイーは強酸性陽イオン
交換樹脂を充填したカラムを用いるものである特
許請求の範囲第１項記載の調製方法。[Scope of Claims] 1. A solution obtained by desalting a filtrate that is a by-product during ultrafiltration of milk or dairy products, or a powder solution obtained by further drying the solution, into a column. A method for preparing L-carnitine, which comprises adsorbing the above liquid or L-carnitine in the solution through chromatography and then eluting it. 2. The preparation method according to claim 1, wherein the desalting treatment is performed by electrodialysis. 3. The preparation method according to claim 1, wherein the column chromatography uses a column packed with a strongly acidic cation exchange resin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60205109A JPS6263553A (en) | 1985-09-17 | 1985-09-17 | Production of l-carnitine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60205109A JPS6263553A (en) | 1985-09-17 | 1985-09-17 | Production of l-carnitine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6263553A JPS6263553A (en) | 1987-03-20 |
| JPH0251543B2 true JPH0251543B2 (en) | 1990-11-07 |
Family
ID=16501568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60205109A Granted JPS6263553A (en) | 1985-09-17 | 1985-09-17 | Production of l-carnitine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6263553A (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4452341B2 (en) | 1999-01-13 | 2010-04-21 | 雪印乳業株式会社 | L-carnitine preparation |
| JP4610111B2 (en) * | 2001-03-19 | 2011-01-12 | 明治乳業株式会社 | Method for measuring L-carnitine in food |
| DE10331202A1 (en) * | 2003-07-10 | 2005-03-31 | S.K. Enterprise Gmbh | Use of whey permeate for the treatment of metabolic syndrome |
| WO2007020973A1 (en) * | 2005-08-18 | 2007-02-22 | Meiji Dairies Corporation | Method of recovering carnitine |
| DE102006036285A1 (en) | 2006-08-03 | 2008-02-07 | "S.U.K." Beteiligungs Gmbh | Whey permeate fractions and their use for the prevention and treatment of type 2 diabetes and metabolic syndrome |
-
1985
- 1985-09-17 JP JP60205109A patent/JPS6263553A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6263553A (en) | 1987-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guo | Whey protein production, chemistry, functionality, and applications | |
| AU620964B2 (en) | Production process of sialic-acids-containing lactose | |
| DE3623474C2 (en) | Process for the extraction of lactotransferrin in milk and pharmaceutical compositions | |
| EP3496543B1 (en) | Process for producing infant formula products and dairy products | |
| WO2018028764A1 (en) | Process for producing infant formula products and acidic dairy products | |
| JP3035833B2 (en) | Method for producing sialic acids-containing composition | |
| JPH0160017B2 (en) | ||
| JPH0251543B2 (en) | ||
| JPH0360468B2 (en) | ||
| DE69110151T2 (en) | Formulated milk for infants analogous to breast milk. | |
| JPH04330252A (en) | Production of composition with high alpha-lactalbumin content | |
| JP4740434B2 (en) | Method for producing polyamine-containing composition | |
| US5085881A (en) | Process for fractionating dried milk products | |
| JP4452341B2 (en) | L-carnitine preparation | |
| AU771611B2 (en) | Novel milk-derived magnesium/calcium materials and methods for producing the same | |
| JP5599446B2 (en) | Prepared milk powder or functional health ingredients using carnitine | |
| JP3850740B2 (en) | Non-protein nitrogen compound derived from milk, L-carnitine concentration method, L-carnitine concentrate and use thereof | |
| JP4465164B2 (en) | Method for producing oligosaccharide containing sialic acid | |
| CA3203492A1 (en) | Demineralised lactose concentrate | |
| JPH02261343A (en) | Preparation of sialic acids-containing desalted condensed milk and desalted milk powder | |
| US2786051A (en) | Growth-promoting substances and their recovery | |
| AU4376600A (en) | Method of producing compositions containing polyamines | |
| Gésan-Guiziou | Extraction of functional food ingredients and nutraceuticals from dairy | |
| JPH02107152A (en) | Production of substitute salt containing milk mineral | |
| JPH02107156A (en) | Production of milk mineral concentrate |